IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 6, June 2026
Impact Factor: 8.2

Huntington's Disease: Genetic Basis, Pathogenesis, Clinical Manifestations, and Emerging Therapeutic Strategies

Rishika Singh
Amity Institute of Biotechnology
Amity University, Lucknow Campus, Lucknow, India
rishikasingh20042004@gmail.com

Abstract: *Huntington's disease (HD) is a genetic neurological condition that progressively impairs a person's mental, cognitive, and motor skills. An aberrant huntingtin protein is produced as a result of the HTT gene's CAG repeats expanding. This mutant protein builds up inside nerve cells and obstructs regular biological processes, which eventually damages and kills neurones. The striatum and cerebral cortex, which are in charge of behaviour, cognition, and motor control, are the brain areas most impacted. Involuntary movements, poor coordination, memory and concentration issues, and a range of psychological symptoms like depression, anxiety, and irritability are typical in people with Huntington's disease. Patients' and their families' quality of life is greatly impacted by these symptoms, which worsen as the illness advances. The precise mechanisms causing neuronal degeneration are still complicated and under investigation, despite the fact that the hereditary aetiology of HD has been recognised for several decades. Recent developments in genetics and molecular biology have expanded our knowledge of the illness and created new therapeutic options. Researchers are investigating novel therapeutic strategies, such as stem cell interventions, RNA-based treatments, antisense oligonucleotides, and gene-silencing technologies. These new approaches seek to limit the disease's course and address the disorder's underlying cause, whereas the majority of present treatments concentrate on managing symptoms.*

The genetic foundation, molecular mechanisms, clinical characteristics, diagnostic techniques, and therapy options for Huntington's disease are all summarised in this review article. Additionally, it covers current advancements in therapeutic research and outlines potential future paths that could lead to better patient outcomes and more efficient disease care. Movement, cognition, and behaviour are all impacted by Huntington's disease (HD), an uncommon hereditary neurological condition. A mutant huntingtin protein is produced as a result of an aberrant expansion of CAG repeats in the HTT gene, which causes the disease. This aberrant protein progressively builds up in nerve cells and interferes with a number of critical cellular functions, leading to progressive loss and damage to neurons. The striatum and cerebral cortex, which are crucial for motor control, memory, and decision-making, are the brain areas most impacted. Involuntary movements, poor coordination, cognitive deterioration, emotional instability, depression, anxiety, and behavioural abnormalities are among the clinical signs of Huntington's disease. The quality of life for patients and their families is greatly impacted by symptoms, which typically start in adulthood and get worse over time. Huntington's disease currently has no known cure, but breakthroughs in molecular biology and genetics have significantly increased our knowledge of its underlying causes.

The primary focus of current treatment options is supportive care and symptom management. However, new therapeutic strategies include RNA-based treatments, antisense oligonucleotides, gene-silencing methods, and stem cell research, which present encouraging prospects for treatment in the future. The

Copyright to IJARSCT
www.ijarsct.co.in
DOI: 10.48175/568

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 6, June 2026
Impact Factor: 8.2

genetic foundation, molecular pathogenesis, clinical characteristics, diagnostic techniques, and recent therapeutic advancements in Huntington's disease are all covered in this overview, which also highlights potential future research and treatment avenues..

Keywords: HTT gene mutation, CAG repeat expansion, mutant huntingtin protein, neurodegeneration, cognitive decline, motor dysfunction, psychiatric symptoms, Huntington's disease, inherited neurological illness, and gene-based therapy

I. INTRODUCTION

A rare but dangerous neurological condition, Huntington's disease (HD) gradually impairs a person's physical, mental, and emotional abilities. George Huntington, an American physician, identified the disease's hereditary basis and distinctive movement anomalies when he first characterised it in 1872. Since then, because of its terrible effects on afflicted people and their families, Huntington's disease has grown to be one of the most researched inherited neurological illnesses.

Because HD is inherited in an autosomal dominant fashion, an individual with the faulty gene has a 50% chance of passing it on to each of their offspring. A mutation in the HTT gene on chromosome 4 is the cause of the illness. A mutant huntingtin protein is produced as a result of this mutation's aberrant increase of CAG trinucleotide repeats. The aberrant protein progressively builds up inside nerve cells and obstructs regular cellular processes, ultimately leading to cell death and neurological malfunction. Many of the motor, cognitive, and behavioural symptoms seen in affected people can be explained by the striatum and cerebral cortex being more susceptible to this injury.

Huntington's disease most frequently manifests in maturity, usually between the ages of 30 and 50. However, there have also been reports of late-onset and juvenile variants of the illness. Mood swings, trouble focusing, impatience, and mild coordination issues are examples of early symptoms, which are frequently mild. As the illness worsens, people experience more severe motor abnormalities like chorea, poor balance, trouble speaking, and difficulty swallowing. The disease burden is further increased by cognitive impairment and mental symptoms as anxiety, depression, and personality abnormalities.

The progressive nature of Huntington's illness is one of its most difficult features. Over time, symptoms progressively deteriorate, increasing reliance on carers and significantly lowering quality of life. The molecular processes causing neuronal degeneration are extremely complicated, despite the fact that the hereditary basis of HD has been recognised for several decades. Numerous physiological mechanisms, including gene regulation, protein degradation, mitochondrial function, and neural signalling, have been found to be disrupted by mutant huntingtin protein. Together, these disruptions lead to the gradual death of neurones and the emergence of clinical signs.

Our knowledge of Huntington's disease has improved recently due to notable developments in genetic and molecular biology research. Innovative therapy strategies that address the underlying genetic issue rather than just treating symptoms have been developed as a result of these discoveries. Antisense oligonucleotides, RNA interference, gene-editing technologies, and stem cell-based therapies are some of the strategies being researched as possible disease-modifying treatments. Even though many of these strategies are still in the experimental phase, they are significant advancements in the creation of more potent treatments.

Reviewing current knowledge of Huntington's disease and assessing new treatment approaches is crucial given the growing understanding of the disease's genetics and molecular underpinnings. This review highlights future avenues for research and illness management by concentrating on the genetic foundation, molecular aetiology, clinical symptoms, diagnostic techniques, and recent therapeutic advancements in Huntington's disease.

Genetics and Molecular Basis of Huntington's Disease-

A mutation in the HTT gene on chromosome 4 (4p16.3) results in Huntington's disease (HD), a genetic neurological condition. An individual only needs one mutant copy of the gene to produce the ailment because it has an autosomal

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 6, June 2026
Impact Factor: 8.2

dominant pattern of inheritance. The disease-causing mutation is therefore 50% likely to be inherited by any kid of an affected parent. Huntington's disease is frequently seen in several generations within the same family, which can be explained by this inheritance pattern.

Huntington's disease is caused by a genetic mutation in the HTT gene that results in the uncontrolled development of a cytosine-adenine-guanine (CAG) trinucleotide repeat sequence. In healthy people, CAG repetitions typically vary from 10 to 35. However, when the repeat number exceeds the normal range, the gene produces an alternative huntingtin protein. Those with 36–39 CAG repeats may or may not experience symptoms throughout their lives, whereas those with 40 or more repeats almost certainly get the illness. Furthermore, a higher number of repeats is usually associated with a more severe illness course and a younger age of onset.

Anticipation is one of the most characteristic hereditary traits of Huntington's disease. This phenomenon describes the disease's propensity to manifest at a younger age in subsequent generations. Because the CAG repeat sequence can extend during transmission from parent to kid, especially through paternal inheritance, anticipation arises. Offspring may therefore inherit a longer repeat expansion than their afflicted parent, raising the possibility that the disease would manifest earlier.

Huntingtin, a big protein that is extensively expressed throughout the body, particularly in the brain, is encoded by the HTT gene. Huntingtin is recognised to perform significant roles in intracellular transport, neuronal development, gene regulation, cell signalling, and the maintenance of neuronal survival, even if its full biological function is yet unknown. A healthy brain depends on huntingtin protein, which also helps nerve cells communicate with one another.

Mutant huntingtin protein (mHTT), which has an unusually long polyglutamine tract, is produced when the CAG repeat expands. The protein's physical characteristics are altered by this structural shift, which makes it unstable and more prone to misfold. Mutant huntingtin that is misfolded has a tendency to build up inside neurones and create intracellular aggregates that obstruct regular cellular functions. These aggregates damage intracellular transport systems, interfere with protein interactions, and exacerbate neuronal dysfunction.

Several biological processes are impacted by mutant huntingtin protein at the molecular level. By changing the activity of proteins involved in gene expression, it disrupts transcriptional control. Numerous genes necessary for neuronal survival and regular brain function are consequently dysregulated. Additionally, mutant huntingtin impairs mitochondrial activity, which raises oxidative stress and decreases energy generation. Neuronal susceptibility and degeneration are greatly influenced by mitochondrial malfunction since neurones need a lot of energy to sustain their functions.

Impaired protein breakdown is another significant biological process. Under normal circumstances, the ubiquitin-proteasome system and autophagy mechanisms eliminate damaged proteins. Toxic protein fragments build up inside cells as a result of mutant huntingtin overpowering these defences. These aberrant proteins' persistence exacerbates cellular stress and encourages neurodegeneration.

Additionally, studies have shown that mutant huntingtin affects neurotransmitter balance and neural transmission. The motor and cognitive symptoms of Huntington's disease have been connected to changes in dopamine and glutamate signalling. Excitotoxicity, a process that destroys neurones by sustained stimulation and contributes to gradual neuronal death, can be brought on by excessive glutamate activity.

The striatum and cerebral cortex are the parts of the brain most negatively impacted by these molecular abnormalities. The hallmark clinical signs of Huntington's disease, including as uncontrollable movements, cognitive impairment, and mental disorders, are caused by neuronal degeneration in these regions. In the end, serious disability and a lower quality of life are caused by the progressive loss of neural structure and function.

Clinical Manifestations of Huntington's Disease-

Huntington's disease (HD) has a wide range of clinical symptoms that get worse over time. A person's everyday life and independence are greatly impacted by the condition, which mostly impairs motor function, cognition, and mental health. Although they might start earlier or later, symptoms often manifest between the ages of 30 and 50.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 6, June 2026 Impact Factor: 8.2

The most obvious signs of the illness are frequently motor complaints. These include muscle twitching, poor coordination, difficulties maintaining balance, irregular gait, and chorea—involuntary motions. Patients may have less voluntary motor control, difficulty swallowing, and trouble speaking as the condition worsens.

Another significant symptom of Huntington's disease is cognitive impairment. People who are affected may experience issues with focus, memory, making decisions, solving problems, and organising everyday tasks. Routine tasks and work performance are gradually hampered by cognitive deterioration.

Additionally prevalent are behavioural and psychiatric problems, which may manifest prior to the manifestation of motor abnormalities. It is common to see depression, anxiety, anger, mood fluctuations, apathy, and social disengagement. Additionally, some people may exhibit aggressive tendencies, compulsive behaviours, or psychotic symptoms.

Motor, cognitive, and mental symptoms worsen as Huntington's disease progresses, resulting in severe disability and reliance on carers. Patients' and their families' quality of life is significantly impacted by the disorder's progressive nature.

Diagnosis and Genetic Testing-

A combination of clinical assessment, family history, neurological examination, and genetic testing is used to diagnose Huntington's disease (HD). A thorough family history frequently offers crucial diagnostic hints since the illness is inherited in an autosomal dominant manner. The absence of a known family history does not, however, rule out the illness.

The evaluation of distinctive symptoms, such as involuntary movements (chorea), poor coordination, cognitive decline, and mental disorders, is the first step in the clinical diagnosis process. Evaluations of motor function, balance, reflexes, and behavioural changes are all aided by neurological exams. Brain imaging methods like computed tomography (CT) scans and magnetic resonance imaging (MRI) can sometimes be used to identify structural alterations in the brain, especially atrophy of the cerebral cortex and striatum.

The most dependable way to confirm Huntington's disease is through genetic testing. The test determines how many CAG trinucleotide repeats are found in the HTT gene. People with 40 or more repeats are quite likely to get the disease, whereas those with less than 26 repeats are thought to be unaffected. Repeat lengths between 36 and 39 may or may not cause clinical symptoms and are linked to decreased penetrance.

For those without symptoms but with a family history of Huntington's disease, predictive genetic testing is an option. This enables those who are at risk to make educated choices about their lifestyle, family planning, and future health. Before and after testing, genetic counselling is highly advised to assist people in comprehending the social, psychological, and physical ramifications of the results.

Participation in clinical research aimed at creating novel therapeutic methods, patient care, and illness management all depend on accurate diagnosis and early genetic testing.

Current Therapeutic Approaches –

Huntington's disease (HD) currently has no known cure, and the majority of available treatments concentrate on symptom management and enhancing the quality of life for those who have it. Treatment typically necessitates a multidisciplinary approach involving neurologists, psychiatrists, physical therapists, speech therapists, and other medical specialists because the condition affects movement, cognition, and mental health.

One of the disease's defining characteristics, chorea, is one of the motor symptoms that are frequently managed with medication. By controlling dopamine levels in the brain, medications like tetrabenazine and deutetrabenazine assist in lessening uncontrollable movements. Antipsychotic drugs may occasionally be used to treat behavioural issues as well as irregularities of mobility.

Antidepressants, anxiety meds, and mood stabilisers are among the relevant medications used to treat psychiatric disorders, such as sadness, anxiety, irritability, and mood swings. Because these symptoms can have a major impact on

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 6, June 2026
Impact Factor: 8.2

a patient's emotional health and day-to-day functioning, it is crucial to treat them as soon as possible. In order to effectively manage a condition, supportive therapies are essential. While occupational therapy helps patients carry out daily tasks more independently, physical therapy aids in maintaining mobility, balance, and muscle strength. In addition to helping with swallowing issues that frequently arise in the later stages of the illness, speech and language therapy can enhance communication abilities.

Since many people with Huntington's disease experience weight loss and increased energy expenditure, nutritional supplementation is also crucial. Maintaining general health and lowering problems can be achieved with a balanced diet and routine nutritional status monitoring.

Current treatment methods can effectively manage symptoms, increase functional ability, and improve the quality of life for patients and their carers, even when they are unable to halt the progression of the disease. The goal of ongoing research is to create therapies that address the disease's root cause and offer long-term advantages.

Emerging Disease-Modifying Therapies-

The discovery of disease-modifying treatments for Huntington's disease (HD) has advanced significantly in recent years. These new methods seek to address the underlying cause of the illness and limit its course, in contrast to traditional treatments that mostly concentrate on managing symptoms.

Gene-silencing therapy is one of the most promising approaches. By focusing on the aberrant HTT gene or its messenger RNA, this strategy aims to decrease the synthesis of mutant huntingtin protein. Short synthetic DNA molecules called antisense oligonucleotides (ASOs) attach to the mutated RNA to stop the dangerous protein from forming. Clinical trials are now being conducted to assess a number of ASO-based treatments.

Another cutting-edge method that lowers the expression of the mutant gene is RNA interference (RNAi). RNAi-based treatments may help prevent neuronal degeneration and slow the progression of disease by reducing the amount of harmful huntingtin protein in nerve cells.

CRISPR-Cas9 and other gene-editing technologies have also garnered a lot of interest. These methods have the ability to directly alter or fix the HTT gene mutation that causes the disease. Gene editing presents a promising long-term approach to treating Huntington's disease at its genetic origin, even though it is still in the experimental stage.

Stem cell treatment is being investigated as a potential way to promote tissue regeneration and replace damaged neurones. Researchers are looking into whether stem cells can help impacted people's neurological outcomes by restoring lost neural function.

Neuroprotective drugs that target oxidative stress, inflammation, and mitochondrial dysfunction are also the subject of several investigations. These treatments seek to lower the rate of neurodegeneration and maintain neuronal health. These methods represent significant advancements in the study of Huntington's disease, even if the majority of them are still being investigated. Future advancements in biotechnology and molecular medicine may result in efficient therapies that can halt or even stop the progression of disease.

Challenges and Future Perspectives-

Despite significant progress in our understanding of Huntington's disease (HD), a number of obstacles still stand in the way of the creation of successful therapies. The complexity of the illness is one of the main challenges. The precise methods by which mutant huntingtin protein damages neurons remain unclear, despite the identification of the genetic mutation causing HD. The development of a single therapy approach that can successfully address every facet of the ailment is challenging due to the involvement of multiple biological pathways in the disease's evolution.

Early illness detection is another significant difficulty. Many pathological alterations start years before clinical symptoms manifest. One of the key areas of research is still finding trustworthy biomarkers for early diagnosis and illness monitoring. Because future disease-modifying treatments are likely to work best before significant neuronal loss has occurred, early diagnosis is crucial.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 6, June 2026
Impact Factor: 8.2

There are a number of challenges in the development of gene-based therapeutics. It is still exceedingly difficult to ensure that therapeutic molecules are delivered to the brain in a safe and effective manner. Before these treatments are made generally accessible, clinical trials must thoroughly assess long-term safety, treatment efficacy, and possible adverse effects.

Future developments in molecular genetics, biotechnology, and neurology should enhance our comprehension of Huntington's disease and facilitate the creation of more focused therapies. Promising prospects for managing diseases in the future are provided by cutting-edge techniques, including gene silencing, genome editing, stem cell treatment, and personalised medicine. Innovative therapeutic approaches, better diagnostic instruments, and ongoing research may someday result in therapies that can stop the onset of symptoms or slow the course of the disease.

II. CONCLUSION

Huntington's disease is a gradual, hereditary neurological condition that profoundly impairs mental, cognitive, and physical abilities. The condition is brought on by an increase in CAG repeats in the HTT gene, which produces a mutant huntingtin protein that causes degeneration and malfunction of neurons. Our knowledge of the genetic and molecular pathways underlying the disease has grown over time thanks to a great deal of study, which has also provided important insights into the disease's pathophysiology and clinical course.

A significant deterioration in quality of life is caused by the complicated clinical manifestations of Huntington's disease, which include a combination of motor abnormalities, cognitive decline, and psychiatric disorders. Even though supportive care and symptom management are the major goals of contemporary therapeutic techniques, they are crucial for enhancing patient well-being and preserving functional independence for as long as possible.

New opportunities for disease-modifying treatments have been made possible by recent developments in biotechnology and molecular medicine. Novel strategies to address the fundamental cause of the disease include gene silencing, antisense oligonucleotides, RNA-based medicines, stem cell research, and genome-editing technologies. Even though many of these tactics are still being researched, they mark a substantial advancement in the creation of more potent therapies.

In conclusion, Huntington's disease continues to be a significant obstacle in both clinical and neurological research. But there is promise for better illness management and better results in the future because of ongoing scientific developments, early diagnosis, better patient care, and the creation of targeted treatments. It is anticipated that ongoing research will be essential to improving the lives of afflicted people and their families, as well as changing the landscape of Huntington's disease therapy.

REFERENCES

[1]. Brás IC, Dawson J, Kay C, Caron NS, Hayden MR. Huntington Disease. In: GeneReviews® [Internet]. Seattle (WA): University of Washington; 2026.
[2]. Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. Huntington's disease. Nat Rev Dis Primers. 2015;1:15005.
[3]. Huntington G. On chorea. Med Surg Reporter. 1872;26:317–321.
[4]. Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin lowering strategies for disease modification in Huntington's disease. Neuron. 2019;101(5):801–819.
[5]. Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10(4):204–216.
[6]. Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep. 2011;11(5):474–483.
[7]. Ghosh R, Tabrizi SJ. Clinical features of Huntington's disease. Adv Exp Med Biol. 2018;1049:1–28.
[8]. McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. Eur J Neurol. 2018;25(1):24–34.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 6, June 2026
Impact Factor: 8.2

[9]. Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurol. 2017;16(10):837–847.
[10]. Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020;16(10):529–546.
[11]. Semaka A, Hayden MR. Evidence-based genetic counseling implications for Huntington disease. Clin Genet. 2014;85(2):101–107.
[12]. Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria and staging of Huntington's disease. Mov Disord. 2014;29(11):1335–1341.
[13]. Caron NS, Dorsey ER, Hayden MR. Therapeutic approaches to Huntington disease: from bench to bedside. Nat Rev Drug Discov. 2018;17(10):729–750.
[14]. Tabrizi SJ, Schobel S, Gantman EC, et al. A biological classification of Huntington disease: the Huntington Disease Integrated Staging System (HD-ISS). Lancet Neurol. 2022;21(7):632–644.
[15]. Walker FO. Huntington's disease. Lancet. 2007;369(9557):218–228.